Request Demo

Last update 11 Nov 2026

Durvalumab

Last update 11 Nov 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Durvalumab (Genetical Recombination), Durvalumab (genetical recombination) (JAN), Durvalumab (USAN/INN)

+ [10]

Target

PDL1

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [12]

Active Indication

Non-Muscle Invasive Bladder NeoplasmsStomach CancerEarly gastric cancer+ [192]

Inactive Indication

Acute Myeloid LeukemiaAdenocarcinoma of LungAdenocarcinoma of prostate+ [103]

Originator Organization

AstraZeneca UK Ltd.

Active Organization

AstraZeneca PLC

AstraZeneca Investment (China) Co. Ltd.AstraZeneca UK Ltd.

+ [19]

Inactive Organization

Fred Hutchinson Cancer Research Center

Plexxikon, Inc.

MedPacto, Inc.

+ [7]

License Organization

MedImmune Pharma BV

Ultimovacs ASAVall d'Hebron Institut d'Oncologia

+ [14]

Drug Highest PhaseApproved

First Approval Date

United States (01 May 2017),

Transitional Cell Carcinoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia)

Structure/Sequence

Sequence Code 10069506H

Source: *****

Sequence Code 13384675L

Source: *****

943

Clinical Trials associated with Durvalumab

NCT07639528

/ Not yet recruitingPhase 2IIT

Phase II, Open Label, Non-Randomized, Study of Optimal Preoperative Therapy for Intrahepatic Cholangiocarcinoma (OPTIC)

This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with intrahepatic cholangiocarcinoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine and/or targeted therapy with futibatinib before surgery may make the tumor smaller for resection and may help prevent the cancer from coming back. Patients whose molecular profiling test result show a genetic change called FGFR2 fusion, rearrangement, or activating mutation, receive immunotherapy, chemotherapy and targeted therapy while patients without a FGFR2 fusion, rearrangement, or activating mutation just receive immunotherapy and chemotherapy. Giving targeted therapy based on molecular profile test results prior to attempted resection for patients with intrahepatic cholangiocarcinoma that has a risk for either not being able to be removed or for coming back after it has been removed may help improve treatment outcomes in patients with resectable intrahepatic cholangiocarcinoma.

Start Date10 Dec 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT07168668

/ Not yet recruitingPhase 2IIT

EXploring Clinical Efficacy of Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment (EXPECT Trial)

Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4; anti-CTLA4) have recently been established as a standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). However, its objective response rate (ORR) is only less than 27% (1, 2), and the majority of patients died of HCC progression and liver failure. Therefore, there is an urgent need to develop a novel combination treatment strategy to overcome resistance to immunotherapy and improve patient outcomes.
Transarterial chemoembolization (TACE) remains the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) (3, 4). However, in our previous retrospective study (5-7), the investigators consistently observed that this combination not only improves therapeutic responses but also significantly prolongs patient survival. The tumor necrosis caused by TACE may enhance the efficacy of systemic therapies by promoting the release of neoantigens, thereby stimulating immune responses (8-14). This concept has been substantiated in two recent trials involving intermediate-stage HCC (15, 16), where the addition of immune checkpoint inhibitors to TACE resulted in improved clinical outcomes. Nevertheless, this promising approach has yet to replace the decades-old standard treatment protocols, underscoring the need for further proof-of-concept studies.
Both immunotherapy (atezolizumab/bevacizumab or durvalumab/tremelimumab) and transarterial chemoembolization (TACE) are approved treatment modalities for unresectable hepatocellular carcinoma (HCC) by the U.S. and Taiwan Food and Drug Administration (FDA). This phase II non-randomized trial is designed to prospectively evaluate the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with a combination of immunotherapy and TACE. A particular focus of this study is to explore the potential immune-boosting effects of TACE, including its ability to enhance antigen presentation and stimulate anti-tumor immune responses.

Start Date01 Feb 2027

Sponsor / Collaborator

Chang Gung Memorial Hospital

NCT05403723

/ SuspendedPhase 1IIT

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Start Date30 Jan 2027

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

100 Clinical Results associated with Durvalumab

100 Translational Medicine associated with Durvalumab

100 Patents (Medical) associated with Durvalumab

2,685

Literatures (Medical) associated with Durvalumab

31 Dec 2026·ANNALS OF MEDICINE

Dose-Registered CT assessment of radiation-induced lung injury after chemoradiotherapy for stage III NSCLC

Article

Author: Sugahara, Shinji ; Ikeda, Norihiko ; Okubo, Mitsuru ; Itonaga, Tomohiro ; Zama, Tatsuhiko ; Mikami, Ryuji ; Saito, Kazuhiro

AIMS:

To quantify radiation-induced lung injury (RILI) on deformably registered CT images after chemoradiotherapy (CCRT) for stage III NSCLC, and to evaluate spatial and dosimetric associations between RILI and planned dose distribution in a pre-durvalumab cohort.

METHODS:

This retrospective study included 58 patients with stage III NSCLC treated with CCRT using three-dimensional conformal radiotherapy (3D-CRT) prior to the era of consolidation immunotherapy. Follow-up CT images at 6 months (acute) and 12 months (late) were registered to treatment planning CT using deformable image registration (DIR). RILI was quantified by segmented volume (mL) and isodose-line overlap (%). Dosimetric parameters (V5Gy-V60Gy, mean lung dose) and symptomatic RILI (CTCAE grade ≥2) were analysed using correlation, ROC, and logistic regression methods.

RESULTS:

Symptomatic RILI occurred in 14 patients (24.1%). RILI volume decreased by 27.7% from the acute to the late phase, with moderate-to-strong dose-volume correlations in both phases (Spearman ρ = 0.69-0.76). Symptomatic patients showed broader spatial spread into lower-dose regions (median isodose-line overlap 20% vs 40%; p < 0.001). Acute-phase RILI reaching the ≤25% isodose line (≤16.5 Gy) was an exploratory imaging marker in this cohort (AUC 0.81) that remained associated with symptomatic RILI on multivariable analysis (p < 0.01).

CONCLUSIONS:

Dose-registered CT analysis demonstrated consistent spatial associations between planned dose and RILI, providing a hypothesis-generating dosimetric-radiographic reference dataset that requires external validation in IMRT/VMAT- and durvalumab-treated cohorts before clinical application.

31 Dec 2026·OncoImmunology

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies

Article

Author: Ilie, Alis ; Truntzer, Caroline ; Flatmark, Kjersti ; Peroz, Morgane ; Derangère, Valentin ; Bousquet, Paula Anna ; Rageot, David ; Ree, Anne Hansen ; Thibaudin, Marion ; Meltzer, Sebastian ; Ghiringhelli, François

BACKGROUND:

Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.

METHODS:

We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone versus chemoimmunotherapy, and evaluated the association between these outcomes and transcriptomic and immunoscore data.

RESULTS:

A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached vs. 15.3 months; HR = 0.58; 95% CI, 0.36-0.96; p = 0.03). The complete response rates were higher with chemoimmunotherapy (14% vs. 5%). No significant differences were observed in PFS. High baseline CD8⁺ T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.

CONCLUSIONS:

This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8⁺ T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.

31 Dec 2026·OncoImmunology

Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

Article

Author: Fidan, Sena ; Engin Delipoyraz, Ebru ; Terzioglu, Cihat ; Cakir, Tansel ; Cakan Demirel, Burcin ; Muglu, Harun ; Kutlu, Yasin ; Hamdard, Jamshid ; Seker, Mesut ; Ozcelik, Hakan ; Sunger, Erdem ; Yucel, Mehmet Haluk ; Bilici, Ahmet ; Acıkgoz, Ozgur ; Mildanoglu, Maral Martin

Growing evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors across multiple malignancies. However, evidence in extensive-stage small cell lung cancer (ES-SCLC) remains limited to a single East Asian cohort, and independent validation in other populations is lacking. We conducted a retrospective single-center cohort study of 107 patients with ES-SCLC treated with first-line platinum-etoposide plus atezolizumab or durvalumab. The time of day of administration (ToDA) was defined as the median start time of the first four immunotherapy infusions, and patients were categorized according to the cohort median ToDA. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The cohort median ToDA was 11:54. Patients treated before the median ToDA had significantly longer median PFS (9.07 vs. 7.23 months, p = 0.002) and OS (21.17 vs. 11.43 months, p = 0.002) than those treated later. In multivariable Cox regression analysis, later administration remained independently associated with shorter PFS (adjusted HR 1.63, 95% CI 1.03-2.58; p = 0.038) and OS (adjusted HR 1.65, 95% CI 1.00-2.71; p = 0.049), whereas objective response rates, treatment-related toxicity, and immune-related adverse events were comparable between groups. Morning administration of first-line chemoimmunotherapy was associated with significantly longer survival without increased toxicity in patients with ES-SCLC. These findings support growing evidence that circadian timing may influence immune checkpoint inhibitor efficacy and warrant prospective evaluation of treatment timing as a readily modifiable strategy to optimize immunotherapy delivery.

1,400

News (Medical) associated with Durvalumab

09 Nov 2026

·www.biospace.com

Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update

Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA. Data from the COMPANION-002 study of tovecimig, including newly disclosed durability of response and crossover-adjusted OS analyses, were published in the Journal of Clinical Oncology and presented at the 2026 ESMO Congress in October. CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions continue to enroll patients with triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer based on earlier responses in these indications. An update on the study is expected later this year. Data demonstrating a novel mechanism of action for CTX-10726 (PD-1 x VEGF-A bispecific antibody) was presented at the SITC Annual Meeting, highlighting its differentiated pro the field. An update on the study is expected later this year. $163 million in cash and marketable securities at the end of Q3 2026, which is expected to fund operations into 2028. BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter 2026 financial results and provided a business update. “The third quarter was a period of sustained execution across our pipeline,” said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors. “We continue to prepare the BLA submission for tovecimig and are working to engage the FDA to bring this important therapy to patients with BTC as quickly as possible. The full COMPANION-002 results, now published in the Journal of Clinical Oncology and presented at ESMO, highlight the strength of the supportive data for tovecimig.” “We are confident in the role tovecimig can play in the biliary tract cancer treatment landscape. We are committed to bringing tovecimig to patients as quickly as possible and the totality of the tovecimig data reinforces the urgency of our engagement with the FDA to define the most efficient path to a BLA submission.” “Our pipeline assets are also nearing very meaningful inflection points in their development. Cohort expansions in patients with triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer are going well for CTX-8371 and we expect to provide an update on the study later this year. Updates from the dose-escalation study of CTX-10726 are also expected on that same timeline and we are particularly excited about the differentiated potential for CTX-10726 in the PD-1xVEGF field based on the novel mechanistic data we just presented at SITC. CTX-10726 was shown to mediate VEGF-dependent cleavage of cell surface PD-1 – effectively turning PD1-positive cells into PD1-negative cells in the presence of VEGF and directly linking tumor angiogenesis with checkpoint inhibition.” Pipeline Updates: Tovecimig (DLL4 x VEGF-A bispecific antibody) BLA submission activities continue as the Company prepares to further engage with the FDA. In September 2026, the Company disclosed that the FDA recommended an additional study demonstrating a survival benefit before submission of a BLA. Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC. Full COMPANION-002 data was published in the peer-reviewed Journal of Clinical Oncology and presented at the 2026 European Society for Medical Oncology (ESMO) Congress. As previously reported, the study met its primary endpoint, with tovecimig plus paclitaxel demonstrating a statistically significant improvement in ORR of 18.0% vs. 5.3% with paclitaxel alone (p=0.0228). The study also met its key secondary endpoint of PFS with a median PFS of 4.7 vs. 2.6 months (HR=0.44, p<0.0001), representing a 56% reduction in the risk of disease progression or death. Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate (DCR) was also significantly improved (62.2% vs. 36.8%). The intent-to-treat overall survival (OS) analysis was confounded by the high rate of crossover and no statistically significant difference in OS was observed. To estimate the treatment effect had crossover not occurred, the JCO publication included a post hoc exploratory analysis using the Two-Stage Estimation, an established method for adjusting crossover, in which the OS hazard ratio was 0.85 (95% CI, 0.59–1.26; p=0.53). The safety pro generally manageable and consistent with prior tovecimig studies and the anti-VEGF class, with no new safety signals identified Enrollment continues in the investigator-sponsored trial (IST) evaluating tovecimig plus first-line standard-of-care gemcitabine, cisplatin and durvalumab in patients with biliary tract cancer (BTC) ( NCT06548412 ), with expansion to additional sites expected. Two additional investigator-sponsored trials (ISTs) of tovecimig are underway in the second-line setting. These include a study of tovecimig plus FOLFIRI in patients with colorectal cancer ( NCT07662031 ) and a now-enrolling novel-novel combination study of tovecimig plus CTX-471 in patients with glioblastoma ( NCT07392957 ). The Company is also evaluating additional ISTs and Company-sponsored studies of tovecimig in other indications. CTX-8371 (PD-1 x PD-L1 bispecific antibody) Cohort expansions for CTX-8371 continue to enroll patients with triple-negative breast cancer (n=28), non-small cell lung cancer (n=28), and Hodgkin lymphoma (n=12) in the post-checkpoint inhibitor setting. These indications were selected based on the deep and durable responses observed in these indications in the dose escalation portion of the study. Half of the patients with each tumor type will be dosed at 3.0 mg/kg and half will be dosed at 10.0 mg/kg. An update on the study is expected later this year. CTX-10726 (PD-1 x VEGF-A bispecific antibody) Data demonstrating a novel mechanism of action for CTX-10726 was presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, highlighting its differentiated potential in the field. In preclinical studies, CTX-10726 was shown to cleave PD-1 receptors from T-cells in tumors expressing high levels of VEGF-A, linking angiogenic signaling directly to checkpoint inhibition. This VEGF-A-mediated effect was seen in vitro and in vivo with CTX-10726, and was not seen with pembrolizumab or bevacizumab. The ongoing Phase 1 multiple ascending dose-escalation study includes four doses (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 dose-escalation design. The multi-center study is enrolling patients with a prioritized set of solid tumor indications, including locally advanced, unresectable or metastatic renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, and endometrial cancer, in whom standard of care therapies have failed. An update on the study is expected later this year. CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered by the Company. CTX-10726 exhibited more potent PD-1 blockade compared with data reported for other drugs in the class in preclinical studies. CTX-471 (CD137 or 4-1BB agonist antibody) Initiation of the Phase 2 trial of CTX-471 in tumors expressing NCAM (CD56) is ongoing. CTX-471 is a monoclonal antibody that targets a novel epitope of CD137 (4-1BB) and the study will evaluate patients with tumors expressing high levels of neural cell adhesion molecule (NCAM or CD56), building on Phase 1 data showing response and disease control were associated with high NCAM expression. The Phase 2 study ( NCT07684170 ) is evaluating CTX-471 as a monotherapy in patients with locally advanced or metastatic Grade 3 NET or NEC, whose tumors are centrally confirmed to be NCAM (CD56)-positive by immunohistochemistry, who have received at least one prior line of chemotherapy, and who have exhausted other standard-of-care options. In stage one of the study, patients will be dosed with CTX-471 at the 0.3 mg/kg (n=18) and 0.6 mg/kg (n=18) dose levels. Advancement to the second stage of the study, with potentially 11 additional patients per dose, will be based on objective response rate. Initial data from the first stage of the study are expected in the second half of 2027. Financial Results Net loss for the quarter ended September 30, 2026, was $27.2 million or $0.15 per common share, compared to $14.3 million or $0.08 per common share for the same period in 2025. Net loss for the nine months ended September 30, 2026, was $70.6 million or $0.38 per common share, compared to $50.8 million or $0.34 per common share for the same period in 2025. Research and Development (R&D) Expenses R&D expenses were $22.0 million for the quarter ended September 30, 2026, as compared to $12.8 million for the same period in 2025, an increase of $9.2 million or 72%. This was primarily driven by $8.6 million of manufacturing costs related to tovecimig. R&D expenses were $55.0 million for the nine months ended September 30, 2026, as compared to $42.3 million for the same period in 2025, an increase of $12.7 million or 30%. This was primarily driven by driven by an increase of $11.1 million of manufacturing expense related to tovecimig. General and Administrative (G&A) Expenses G&A expenses were $6.8 million for the quarter ended September 30, 2026, as compared to $3.0 million for the same period in 2025, an increase of $3.8 million or 126%. This was primarily driven by an increase of $1.8 million in stock-based compensation expense and $1.5 million of pre-commercialization expenses. G&A expenses were $21.1 million for the nine months ended September 30, 2026, as compared to $12.7 million for the same period in 2025, an increase of $8.5 million or 68%. This was primarily driven by an increase of $3.8 million of stock-based compensation expense and $4.6 million of pre-commercialization expenses. Cash Position As of September 30, 2026, cash and marketable securities were $163 million as compared to $209 million as of December 31, 2025. The decrease was primarily driven by $48 million used in operating activities. Based on current operating plans, the anticipated cash runway is into 2028. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans, interactions, and potential pathways with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at , including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC. Investor Contact ir@compasstherapeutics.com Media Contact Anna Gifford, Chief of Staff media@compasstherapeutics.com 617-500-8099 Compass Therapeutics, Inc. and Subsidiaries Consolidated Statement of Operations (unaudited) (In thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Operating expenses: Research and development $ 22,039 $ 12,826 $ 55,001 $ 42,297 General and administrative 6,761 2,991 21,077 12,552 Loss from operations (28,800 ) (15,817 ) (76,078 ) (54,849 ) Interest income 1,629 1,558 5,436 4,076 Net loss $ (27,171 ) $ (14,259 ) $ (70,642 ) $ (50,773 ) Net loss per share - basic and diluted $ (0.15 ) $ (0.08 ) $ (0.38 ) $ (0.34 ) Basic and diluted weighted average shares outstanding 186,798 168,782 186,667 148,545 Compass Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except par value) September 30, 2026 December 31, 2025 (unaudited) Assets Current assets: Cash and cash equivalents $ 41,469 $ 30,643 Marketable securities 121,589 178,263 Prepaid expenses and other current assets 2,439 913 Total current assets 165,497 209,819 Property and equipment, net 402 102 Operating lease, right-of-use ("ROU") asset 8,031 9,099 Other assets 568 568 Total assets $ 174,498 $ 219,588 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,316 $ 1,585 Accrued expenses 16,378 11,383 Operating lease obligations, current portion 1,674 1,000 Total current liabilities 24,368 13,968 Operating lease obligations, long-term portion 7,560 8,829 Total liabilities 31,928 22,797 Total stockholders' equity 142,570 196,791 Total liabilities and stockholders' equity $ 174,498 $ 219,588

Phase 1Clinical ResultImmunotherapyFinancial StatementPhase 2

06 Nov 2026

·www.biospace.com

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG , Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resectable non-small cell lung cancer (NSCLC) have been published in the journal Nature Medicine . This Phase II trial assessed the efficacy and safety of perioperative ivonescimab administered either as monotherapy or in combination with chemotherapy. Patients received neoadjuvant treatment followed by surgical resection and subsequent adjuvant ivonescimab. The study demonstrated that neoadjuvant ivonescimab in combination with chemotherapy produced high rates of pathological response in patients with resectable NSCLC. Among patients who underwent surgery, the major pathological response (MPR) rate was 70.1% and the pathological complete response (pCR) rate was 50.7%. Key findings: In the ivonescimab plus chemotherapy cohort, the MPR rate reached 70.1%, the pCR rate was 50.7%, and 68.7% of patients had residual viable tumor (RVT) ≤5%. The ivonescimab monotherapy cohort also showed meaningful pathological responses, with an MPR rate of 60.0% and a pCR rate of 30.0%. Both cohorts achieved high objective response rates and frequent T-stage downstaging. All patients who proceeded to surgery achieved R0 resection (100%). The 12-month event-free survival (EFS) rates exceeded 80% in both arms, comparing favorably with outcomes reported in prior Phase III perioperative immunotherapy trials. Subgroup analyses revealed particularly notable activity in clinically relevant populations: patients with squamous histology achieved an MPR rate of 81.5% and a pCR rate of 61.1%; those with Stage III disease achieved an MPR rate of 65.5% and a pCR rate of 47.3%; and PD-L1-negative patients achieved an MPR rate of 69.2%, comparable to that observed in PD-L1-positive patients. The perioperative safety pro ivonescimab was manageable. No grade ≥3 bleeding events occurred, and no surgeries were cancelled due to treatment-related adverse events. Approximately one-quarter of patients with NSCLC have resectable disease at the time of diagnosis. Nevertheless, 30–70% of patients experience disease recurrence after surgery, frequently with distant metastases, contributing to poor long-term outcomes. Although neoadjuvant immuno-chemotherapy is now established in treatment guidelines, current regimens leave room for improvement, particularly in subgroups such as Stage IIIB disease, squamous histology, and PD-L1-negative tumors, where unmet clinical need remains substantial. These Phase II results further support the potentially important role of ivonescimab as a next-generation immunotherapy option across the continuum of NSCLC treatment options. About Ivonescimab Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by Akeso. It is the world's first approved bispecific antibody that combines immuno-oncology and anti-angiogenesis mechanisms in a single molecule, helping to define a new generation of bispecific immuno-oncology therapies. Ivonescimab is also the first therapy to demonstrate positive results in a Phase III head-to-head study against pembrolizumab. Building on its strong clinical pro the IO2.0 landscape, Akeso is advancing a comprehensive global development program for ivonescimab across multiple tumor types and treatment settings. As a cornerstone of the Company's IO2.0 + ADC2.0 strategy, ivonescimab aims to help reshape standards of care in major cancers worldwide. More than 17 Phase III studies of ivonescimab are underway globally, including seven international multi-regional registrational Phase III trials and seven head-to-head studies versus PD-1/PD-L1 therapies. These programs encompass eight registrational or Phase III studies in lung cancer, as well as trials in first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with ligufalimab versus pembrolizumab), first-line biliary tract cancer (versus pembrolizumab/ durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial carcinoma (versus pembrolizumab plus a Nectin-4 ADC). Akeso has out-licensed the exclusive rights to develop and commercialize ivonescimab in the United States and Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to US$5 billion. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval. Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world. Forward-Looking Statements This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. View original content to download multimedia: SOURCE Akeso, Inc.

Clinical ResultPhase 3Phase 2License out/inImmunotherapy

05 Nov 2026

·www.biospace.com

AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer

New investor presentation outlines scientific rationale for combining Ampligen’s immune-stimulating activity with daraxonrasib’s targeted RAS inhibition to potentially prolong clinical benefit Previously reported Ampligen clinical observations support further investigation in pancreatic cancer Phase 2 DURIPANC topline results expected in Q1 2027, with additional clinical and immune-response analyses anticipated in Q3 2027 Access the presentation here OCALA, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new investor presentation, “ The Ampligen Opportunity ,” highlighting the potential for Ampligen (rintatolimod) to complement emerging RAS-targeted therapies in pancreatic cancer, including Revolution Medicines’ Rasonque™ (daraxonrasib). The presentation examines recent advances in pancreatic cancer treatment and the scientific rationale for combining RAS inhibition with immune stimulation to potentially enhance and extend clinical benefit. It also highlights previously reported Ampligen clinical observations, the ongoing Phase 2 DURIPANC program and anticipated 2027 milestones. AIM Chief Executive Officer Thomas K. Equels states: “Ampligen has been demonstrated to be a powerful innate immunomodulator with broad-spectrum anti-tumor proliferation effects, while the RAS-targeted therapy daraxonrasib represents a new and promising development which, I believe, will likely become a first-line therapy for pancreatic cancer. I see great potential in bringing the two together. While daraxonrasib targets the signaling pathways that drive tumor growth, Ampligen is designed to stimulate innate and adaptive immune responses, which helps set Ampligen apart among late-stage clinical trials for pancreatic cancer. We believe these potentially complementary mechanisms of action provide a compelling foundation for investigating how Ampligen might enhance and prolong the benefits of targeted RAS treatment, which is especially significant because of daraxonrasib’s potential to become the standard of care therapy for pancreatic cancer in the very near future.” Key Highlights from the Investor Presentation Daraxonrasib’s Phase 3 Results and the Potential for Complementary Treatment Strategies The presentation highlights results from the randomized Phase 3 RASolute 302 study evaluating daraxonrasib against investigators’ choice of chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. In the overall study population, daraxonrasib demonstrated: Median overall survival of 13.2 months versus 6.7 months with chemotherapy (hazard ratio: 0.40). Median progression-free survival of 7.2 months versus 3.6 months with chemotherapy (hazard ratio: 0.49). These findings underscore the progress being made in RAS-targeted treatment and the opportunity to investigate strategies that may further extend disease control. Complementary Mechanisms Support Further Investigation Daraxonrasib inhibits RAS(ON) signaling involved in tumor growth, while Ampligen is an investigational Toll-like receptor 3 (TLR3) agonist designed to stimulate innate and adaptive immune responses. Previously published research involving Ampligen has demonstrated immune modulation involving dendritic cells and T-cell responses. AIM believes these distinct mechanisms support further investigation of whether Ampligen could enhance anti-tumor immune activity alongside RAS inhibition. The proposed combination remains investigational, and its safety, efficacy and potential to improve outcomes beyond daraxonrasib alone have not been established. Previously Reported Ampligen Clinical Observations Provide an Encouraging Foundation The presentation highlights findings from a Netherlands government-approved Named Patient Program evaluating Ampligen following FOLFIRINOX chemotherapy in patients with advanced pancreatic cancer. In this nonrandomized program, 57 Ampligen-treated patients were compared with 27 historical controls. Exploratory findings included: Median overall survival of 19.7 months versus 12.5 months in historical controls. Median progression-free survival of 12.6 months versus 8.6 months in historical controls. Median overall survival of 34.8 months in an Ampligen-treated subgroup with a baseline neutrophil-to-lymphocyte ratio of 4.5 or less, versus 19.3 months among Ampligen-treated patients with higher ratios. DURIPANC Program Advancing Toward Key 2027 Clinical Milestones AIM’s ongoing Phase 1/2 DURIPANC study is evaluating Ampligen in combination with durvalumab (Imfinzi ® ) in patients with metastatic pancreatic cancer who achieved stable disease following FOLFIRINOX chemotherapy. The study enrolled 28 patients across Phase 1 and Phase 2. The Phase 2 primary endpoint is clinical benefit rate at 24 weeks. To date, the clinical trial has met each milestone on schedule. Previously reported interim findings include encouraging tolerability, with only three Grade 3 immune-related adverse events; consistently high patient-reported quality of life; and preliminary evidence of coordinated innate and adaptive immune activation. AIM anticipates the following milestones: Q1 2027: Phase 2 topline results evaluating clinical benefit rate at 24 weeks. Q3 2027: Additional analyses of overall survival, progression-free survival, quality of life and immune responses. These findings are expected to help inform future development opportunities, including the potential design of a pivotal Phase 3 trial. Exploring the Potential to Extend RAS-Targeted Treatment Benefits The presentation also outlines a proposed development strategy to investigate whether adding Ampligen to ongoing daraxonrasib treatment, or as a post-daraxonrasib maintenance therapy, could strengthen anti-tumor immune responses and potentially extend disease control. Potential evaluations include safety, biological activity, treatment timing, progression-free survival and duration of response. This proposed strategy is not an established clinical trial protocol, and additional research would be required to evaluate the combination. Positioning Ampligen for the Evolving Pancreatic Cancer Treatment Landscape As RAS-targeted therapies continue to advance, AIM believes Ampligen’s immunomodulatory mechanism and existing clinical observations provide a foundation for exploring complementary treatment strategies. With anticipated DURIPANC milestones in 2027, the Company remains focused on generating additional clinical evidence while evaluating opportunities to expand Ampligen’s potential role in pancreatic cancer treatment. The Company’s new investor presentation, “ The Ampligen Opportunity ,” is available here . About Ampligen ® Ampligen ® (rintatolimod) is an investigational immunomodulatory drug that acts through Toll-like receptor 3 (TLR3) signaling. It is being investigated for its potential to stimulate innate and adaptive immune responses across multiple disease settings, including cancer. In pancreatic cancer, research has demonstrated immune modulation involving dendritic-cell-mediated T-cell responses. Ampligen is not approved by the U.S. Food and Drug Administration for the treatment of pancreatic cancer. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen ® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials. For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook . Trademark Note Rasonque™ is a registered trademark of Revolution Medicines Inc. AIM ImmunoTech is not affiliated with, sponsored by, or endorsed by Revolution Medicines Inc. Cautionary Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: the potential of Ampligen to enhance and extend clinical benefit; the potential of combined treatment approaches to pancreatic cancer; the potential for any such effect to be durable or long-lasting; Ampligen’s potential to complement existing therapies and to overcome biological barriers that have limited treatment success in pancreatic cancer; the timing, conduct and outcome of the DURIPANC primary endpoint analyses, biomarker evaluations and overall survival follow-up; the timing and outcome of planned regulatory interactions; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen ® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen ® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks. For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at and You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

Phase 2ImmunotherapyClinical ResultPhase 3

100 Deals associated with Durvalumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10808	Durvalumab	L01FF03	DB11714

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	United States	AstraZeneca UK Ltd.	28 May 2026
Stomach Cancer	European Union	AstraZeneca AB	16 Mar 2026
Stomach Cancer	Iceland	AstraZeneca AB	16 Mar 2026
Stomach Cancer	Liechtenstein	AstraZeneca AB	16 Mar 2026
Stomach Cancer	Norway	AstraZeneca AB	16 Mar 2026
Early gastric cancer	United States	AstraZeneca PLC	25 Nov 2025
Gastroesophageal junction adenocarcinoma	United States	AstraZeneca UK Ltd.	25 Nov 2025
Gastrooesophageal junction cancer	United States	AstraZeneca PLC	25 Nov 2025
Locally Advanced Gastric Carcinoma	United States	AstraZeneca PLC	25 Nov 2025
Unresectable Lung Non-Small Cell Carcinoma	China	AstraZeneca UK Ltd.	18 Nov 2025
Muscle Invasive Bladder Carcinoma	United States	AstraZeneca UK Ltd.	28 Mar 2025
Uterine Neoplasms	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	22 Nov 2024
Advanced Endometrial Carcinoma	European Union	AstraZeneca AB	15 Aug 2024
Advanced Endometrial Carcinoma	Iceland	AstraZeneca AB	15 Aug 2024
Advanced Endometrial Carcinoma	Liechtenstein	AstraZeneca AB	15 Aug 2024
Advanced Endometrial Carcinoma	Norway	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	European Union	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	Iceland	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	Liechtenstein	AstraZeneca AB	15 Aug 2024
Recurrent Endometrial Cancer	Norway	AstraZeneca AB	15 Aug 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	NDA/BLA	China	AstraZeneca AB	21 Feb 2025
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	AstraZeneca UK Ltd.	21 Feb 2025
Ovarian Epithelial Carcinoma	NDA/BLA	China	AstraZeneca UK Ltd.	16 Aug 2024
MSS/pMMR/MSI-L Solid Tumor	Phase 3	Spain	AstraZeneca PLC	30 Dec 2024
Advanced Neuroendocrine Carcinoma	Phase 3	Japan	AstraZeneca KK	01 Dec 2023
Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	Japan	AstraZeneca KK	01 Dec 2023
Small Cell Carcinoma	Phase 3	Japan	AstraZeneca KK	01 Dec 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	United States	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	China	AstraZeneca PLC	23 Nov 2023
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Japan	AstraZeneca PLC	23 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06083454 (CTgov)	Phase 1	Non-Small Cell Lung Cancer	1	Durvalumab (Durvalumab as Monotherapy)	smrafxndwn(pjwrpmdinn) = tsbvkvyfbk bqsxhcnvhv (jsiulinmtu, vxlcffcwnh - sudmkimbio) View more	-	10 Nov 2026
				Pharmacological ascorbate+Durvalumab (Combination of Pharmacological Ascorbate Plus Durvalumab)	amekknjpmd = zhezidicwr difeibhiqb (gjnbebxgkn, ziddjtqemw - ajcrahrahx) View more
AASLD2026	Not Applicable	Unresectable Intrahepatic Cholangiocarcinoma TP53 mutations	41	gemcitabine, cisplatin, and durvalumab (GCD) or gemcitabine, cisplatin, and pembrolizumab (GCP)	jdqiazuifg(bxjoqqyjib) = vimnbqezmj kkdwzierho (yzefmcdcbk, 4.4 - 10.7) View more	Positive	05 Nov 2026
				gemcitabine, cisplatin, and durvalumab (GCD) or gemcitabine, cisplatin, and pembrolizumab (GCP) (TP53 wild-type ICC)	jdqiazuifg(ofmhyvpwnf) = zaaglglnkr lsqqbftndf (copvyxkfww, 4.4 - 10.7) View more
AASLD2026	Not Applicable	Unresectable Hepatocellular Carcinoma First line	90	Tremelimumab plus durvalumab	dkikgrrmbi(bggxlbgzth) = avhiyvgfvu okckwhonro (vaszcesona, 1.5 - 5.9) View more	Positive	05 Nov 2026
				Tremelimumab plus durvalumab (patients with Vp4 PVTT)	cvohjyovlw(khlevyxekt) = xsbfdvbjfs vmswdtfmyv (abvhjxpjne ) View more
AASLD2026	Phase 2/3	Advanced biliary tract cancer First line	3,000	Durvalumab + Gemcitabine + Cisplatin	wblludrrli(wbebzamjri): HR = 0.74 (95.0% CI, 0.63 - 0.87)	Positive	05 Nov 2026
				Pembrolizumab + Gemcitabine + Cisplatin
AASLD2026	Not Applicable	Hepatocellular Carcinoma First line	1,487	Durvalumab-based regimens	jesvclbzyj(paameyqfdc) = rmpljxthct naovuvjrdj (fmgcyvobej ) View more	Positive	05 Nov 2026
				atezolizumab+bevacizumab	wuegskkytp(guzxbyqsdq) = ehopkhspdj ijzwtgermq (jhwpezfzcu )
NCT03116529 (NEXIS, CTgov)	Phase 1/2	Soft Tissue Sarcoma	22	Combination Radiation, Immunotherapy, Surgery	qipxbtxtso = raemmfqvjh ehkevyuyzf (mpysyftdty, aprfxayozk - izbkontuzx) View more	-	05 Nov 2026
NCT05925530 (MDT-BRIDGE, Pubmed \| Nat Med)	Phase 2	Resectable Lung Non-Small Cell Carcinoma Neoadjuvant	142	Neoadjuvant durvalumab plus chemotherapy	rbpxteodex(vobnurpymc) = ognqgfspzq hfucdycqgc (mojskqoqcz ) View more	Positive	26 Oct 2026
NCT06211036 (DeLLphi-305, Pubmed \| N Engl J Med)	Phase 3	Extensive stage Small Cell Lung Cancer Maintenance	563	Tarlatamab-Durvalumab	ttrabawwjy(pxzjmaghpv) = sdzjgljumn lpcnxrfyxu (wgxrbobgml, 20.8 - NE) View more	Positive	24 Oct 2026
				Durvalumab	ttrabawwjy(pxzjmaghpv) = vjgqgrmnie lpcnxrfyxu (wgxrbobgml, 11.2 - 14.8) View more
NCT03704480 (IMMUNO-BIL, ESMO2026)	Phase 2	Biliary Tract Neoplasms Second line	80	durvalumab + tremelimumab	wxlqrmteng(wuydkdtogj) = vdorocrwud ehpcacnywu (ssdcxkxkij ) View more	Positive	23 Oct 2026
TOPAZ-1 (ESMO2026)	Phase 2	Advanced biliary tract cancer	35	Endoscopic radiofrequency ablation (RFA) combined with Gemcitabine, Cisplatin, and Durvalumab (GCD)	hidpqjwlyw(uwmknhgfgi) = qniqibovcb wmebwignej (fsryqvypjg, 21.5 - 55.1) View more	Positive	23 Oct 2026
				Gemcitabine, Cisplatin, and Durvalumab (GCD)	bnbvomkydw(dxbhvjyzkp) = smscfnwbzo ollalhldfr (ilbnlydopk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis